<a href='https://brc.riken.jp/mus/pcr01708'>Genotyping protocol -PCR-</a> human RFP/RET cDNA, mouse MT-I promoter-enhancer, SV40 splicing signal-polyadenylation site, vector sequence Masashi KATO 条件を付加する。利用者は事前に寄託者の提供承諾書を得る。<br>寄託者(開発者)の承諾を得る。利用者が本件リソースを使用して得られた研究成果に基づき特許等の申請及び事業活動を行う場合は、寄託者と別途協議を行う。共同研究。 Chubu Univ. メタロチオネインプロモーター制御下でがん遺伝子RETを発現するトランスジェニックマウス。皮膚黒色症モデル。腫瘍は発症しない。RET Tgホモは致死。 Mouse Models for Human Disease Developed by Masashi Kato, Nagoya University Graduate School of Medicine. The Mt1-RET transgene was injected into the fertilized eggs of (BALB/c x C57BL/6) x BALB/c mice. C57BL/6 and BALB/c mixed background. RBRC01708 名古屋大学大学院医学系研究科・加藤昌志。(BALB/c x C57BL/6) X BALB/cへトランスジーンのインジェクションにより作出。C57BL/6およびBALB/cの混合背景。 加藤 昌志 中部大学 Necessary documents for ordering:<ol><li>Approval form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_6.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_d.docx">English</A>)</li><li>Order form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_4.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_b.docx">English</A>)</li><li>Category I MTA: MTA for distribution with RIKEN BRC (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_5.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_c.docx">English</A>)</li><li>Acceptance of responsibility for living modified organism (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_7.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_g.docx">English</A>)</li></ol> C (3-6 months) Cancer Research 242 RET 242 RET The RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR. The RECIPIENT of BIOLOGICAL RESOURCE must obtain a prior written consent on use of it from the DEPOSITOR/DEVELOPER. The RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use with the results from the use of the BIOLOGICAL RESOURCE. The RECIPIENT agrees to use this BIOLOGICAL RESOURCE as a collaboration with the DEPOSITOR. メタロチオネインプロモーター制御下でがん遺伝子RETを発現するトランスジェニックマウス。皮膚黒色症モデル。腫瘍は発症しない。RET Tgホモは致死。, Carrier x Noncarrier Carrier x Noncarrier B6.Cg-Tg(Mt1-RET)242Ina B6.Cg-Tg(Mt1-RET)242Ina true Dermatology Research Mt1-Ret 242 transgenic mice. The mice express the human RET under the control of the mouse MT1 promoter/enhancer. Mt1-RET homozygous mutant mice are embryonic lethal. C(3〜6か月)